drugset / Trial / NCT04464564
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study was conducted to evaluate the efficacy, safety, and tolerability of AVP-786 (deudextromethorphan hydrobromide \[d6-DM\]/quinidine sulfate \[Q\]) compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
Timeline
- Start
- 2020-09-11
- Primary completion
- 2024-06-28
- Completion
- 2024-06-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Deudextromethorphan | Unknown | 18 mg | Oral |
| Subject | Deudextromethorphan | Unknown | 42.63 mg | Oral |
| Subject | Quinidine | Small molecule | 4.9 mg | Oral |
Indications
No indication recorded.